rs11204971 — FLG FLG locus regulatory variant

Regulatory tag SNP in the filaggrin (FLG) locus associated with reduced FLG expression and elevated atopic dermatitis risk — strongly enriched in East Asian populations where the G allele reaches 57% frequency

See your personal result for FLG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FLG Locus — Skin Barrier Regulation and the Atopic March

Filaggrin is the key structural protein of the outermost skin layer. Encoded by the FLG gene at chromosome 1q21.3, it aggregates keratin filaments into the waterproof matrix of the stratum corneum11 aggregates keratin filaments into the waterproof matrix of the stratum corneum
Profilaggrin is cleaved into 10–12 filaggrin monomers during terminal epidermal differentiation; the monomers compact keratin and their breakdown products form NMF — the mixture of amino acids, urocanic acid, and urea that keeps skin hydrated and acidic. When filaggrin levels are reduced — through coding mutations that eliminate protein entirely, or through regulatory variants that lower expression — transepidermal water loss rises, skin pH increases, and gaps form between surface skin cells that allow environmental allergens to penetrate and trigger immune sensitization.

rs11204971 is a regulatory tag SNP in the FLG locus identified in genome-wide association studies of atopic dermatitis in Chinese Han populations. Unlike the classic loss-of-function coding mutations (R501X, 2282del4, S3247X) that are common in Europeans, this variant tags a haplotype associated with reduced FLG expression — it marks a regulatory change in how much filaggrin the skin produces rather than making a truncated or absent protein. The G allele shows a striking population distribution: approximately 57% frequency in East Asians compared to 14% in Europeans and 4% in Africans, reflecting the distinct spectrum of FLG variation across ancestry groups.

The Mechanism

The FLG locus at 1q21.3 is regulated by a complex of enhancers and intronic elements that control filaggrin expression during terminal epidermal differentiation. Regulatory SNPs in this region can alter transcription factor binding, splicing efficiency, or enhancer activity without changing the protein sequence. Reduced filaggrin from regulatory variants produces the same downstream consequences as loss-of-function coding mutations — insufficient natural moisturizing factor (NMF)22 natural moisturizing factor (NMF)
a hygroscopic mixture of amino acids, urocanic acid, pyrrolidone carboxylic acid, urea, and ions derived from filaggrin breakdown that retains water in the stratum corneum and maintains the acidic skin pH that suppresses pathogens, elevated transepidermal water loss, and a permissive state for percutaneous allergen entry. The magnitude of effect for regulatory variants is typically smaller than for null coding mutations, but the mechanism is identical.

The Evidence

The FLG 1q21.3 locus was confirmed in a large Chinese Han GWAS33 large Chinese Han GWAS
Sun et al. 2011: 1,012 AD cases and 1,362 controls in discovery, 3,624 cases and 12,197 controls in replication, plus 1,806 German cases; tag SNP rs3126085 showed OR=0.82 (P=5.90×10⁻¹²) for the protective allele and across European populations. rs11204971 was used alongside rs3126085 as a secondary tag SNP for this locus in follow-up Chinese Han studies44 follow-up Chinese Han studies
Tang et al. 2012: examined rs11204971 and rs3126085 alongside three other AD susceptibility SNPs, finding FLG association with AD but not asthma in 463 asthma cases and 985 controls — suggesting distinct genetic architectures for the two atopic conditions.

The broader FLG literature — built primarily on coding loss-of-function mutations but applicable to regulatory variants through the same mechanism — shows robust effects. A meta-analysis of 24 studies55 meta-analysis of 24 studies
Van den Oord & Sheikh 2009: 5,791 eczema cases, 26,454 controls; asthma analysis in 17 studies found FLG haploinsufficiency associated with eczema at OR 3.12 (95% CI 2.57–3.79) and the combined eczema-plus-asthma phenotype at OR 3.29. Importantly, the asthma association was only present in the context of existing eczema — FLG variants do not independently predispose to asthma absent skin barrier disruption — supporting a percutaneous sensitization model where allergens breach the defective skin barrier, trigger IgE-mediated sensitization, and drive the downstream atopic march.

Practical Actions

The central intervention for reduced filaggrin expression is external barrier support. Ceramide-dominant emollients66 Ceramide-dominant emollients
formulations containing ceramides, cholesterol, and free fatty acids in approximately a 3:1:1 molar ratio most closely replicate the physiologic lipid composition of the stratum corneum compensate for reduced NMF production. A randomized controlled trial77 randomized controlled trial
Simpson et al. 2014: 124 high-risk neonates randomized to daily full-body emollient vs no treatment from birth found daily emollient application from birth cut the cumulative incidence of atopic dermatitis by 50% (RR 0.50; 95% CI 0.28–0.90).

Barrier-disrupting personal care ingredients — sodium lauryl sulfate, fragrance, methylisothiazolinone — penetrate compromised skin more readily and cause disproportionate damage when filaggrin levels are suboptimal. Eliminating these from daily products is a high-leverage, low-risk intervention for G allele carriers.

For infants of G allele carriers, particularly those of East Asian ancestry where the G allele is common and AD prevalence is high, early introduction of common food allergens and emollient prophylaxis from birth represent the two most evidence-supported prevention strategies for interrupting the atopic march.

Interactions

rs11204971 tags the same FLG locus haplotype as rs3126085 and co-listed rs12123821. These variants are in linkage disequilibrium and reflect the same underlying biology — reduced filaggrin expression through regulatory mechanisms at 1q21.3. Carriers of classical FLG null coding mutations (rs61816761 / R501X, rs558269137 / 2282del4) have a more severe baseline because those mutations eliminate protein from the affected allele entirely, compared to the partial expression reduction from regulatory variants. When a person carries both a regulatory variant (rs11204971 G) and a coding null mutation on the other chromosome, the combined effect approaches that of compound heterozygosity for two null alleles.

rs11204971 shows no independent association with asthma in the absence of atopic dermatitis, which is consistent with the percutaneous sensitization model: FLG-driven systemic Th2 skewing requires active barrier disruption and allergen penetration through eczematous skin.

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal expression Normal

Common FLG locus genotype — normal filaggrin expression expected

You carry two copies of the reference A allele at this FLG locus position, which is associated with normal filaggrin expression. This genotype is found in approximately 72% of the global population and is the dominant genotype in people of African ancestry (approximately 92% AA). About 73% of Europeans and 18% of East Asians carry this genotype. No elevated risk for atopic dermatitis or skin barrier disruption is associated with this variant based on current evidence.

AG One risk haplotype Intermediate

One copy of the FLG risk haplotype — moderately elevated atopic dermatitis susceptibility

Filaggrin expression from the G-allele haplotype is reduced relative to the A-allele haplotype through regulatory mechanisms at the 1q21.3 locus — likely altered transcription factor binding or enhancer activity affecting how much FLG is transcribed during terminal epidermal differentiation. Lower filaggrin means less natural moisturizing factor (NMF), higher transepidermal water loss, and a mildly compromised barrier that is more permissive to allergen penetration than in AA individuals.

The clinical impact of heterozygosity for this regulatory variant is subtler than for coding null mutations: many AG carriers will have no eczema symptoms, and the variant contributes modest odds of atopic dermatitis rather than the OR 3.1 seen for coding null allele heterozygotes. In East Asian populations where the G allele is common, AD risk from this locus is a population-level contributor rather than a marker of extreme individual risk. Nonetheless, the same barrier-support logic applies: maintaining skin hydration and avoiding barrier-disrupting personal care ingredients reduces cumulative barrier stress even without overt eczema.

GG Two risk haplotypes High Risk

Two copies of the FLG risk haplotype — elevated atopic dermatitis risk, particularly in East Asian individuals

When both FLG haplotypes carry the reduced-expression G allele, the cumulative effect on filaggrin levels may approach that of heterozygosity for a coding null mutation — both chromosomes are producing less filaggrin than their reference counterparts. The downstream consequence is a skin barrier operating with substantially below-average NMF levels, elevated transepidermal water loss, and a higher-than-normal risk that environmental allergens (house dust mite, food proteins, pollen) will penetrate to viable epidermis and trigger IgE sensitization.

In East Asian populations, GG is the most common single genotype at this locus (more common than AA at ~32% vs 18%), so a large proportion of East Asian individuals with atopic dermatitis will carry this genotype. The risk attributable to GG is additive over AG in an additive inheritance model. If you have personal or family history of atopic dermatitis, asthma, or food allergy — especially if you are of East Asian or South Asian ancestry — GG at this locus is an expected finding that explains some of that susceptibility through reduced filaggrin production.

Note that this regulatory variant produces a different effect profile than coding null mutations: both alleles produce some filaggrin (reduced expression), rather than one allele producing none (null mutations). This means GG homozygotes here are unlikely to show the overt ichthyosis or keratoderma seen in FLG null homozygotes, but may still have chronic atopic dermatitis and barrier vulnerability.